An inducible signal 1 booster overcomes limited access to antigen for solid tumor cell therapy

Molecular Therapy: Oncology · Published 2026-08-01 · DOI 10.1016/j.omton.2026.201315

Free full text

Authors (12)

Kelly C. Radecki, Diane Manry, Charles Kirsh, Navneet Kumar, Ethan McLeod, Anagha Krishnagiri, Aaron D. Flynn, Alaia Sima, Julyun Oh, Alexander C. Partin, Breanna DiAndreth, Alexander Kamb

Abstract

PubPorta does not have an abstract for this article yet.

Read the article at the publisher →

Publication details

Year

2026

Citation

Radecki, K., Manry, D., Kirsh, C., et al. (2026). An inducible signal 1 booster overcomes limited access to antigen for solid tumor cell therapy. Molecular Therapy: Oncology. https://doi.org/10.1016/j.omton.2026.201315

Related articles

• Rethinking lymphodepleting preconditioning in adoptive T cell therapy for durable tumor control · Molecular Therapy: Oncology · 2026 · Same journal
• Depletion of IL-10 in CAR-NK cells augments reprogramming of the tumor microenvironment and ameliorates therapeutic efficacy · Molecular Therapy: Oncology · 2026 · Same journal
• AGTR1 signaling contributes to tumor immunity and therapy response in non-small cell lung cancer · Molecular Therapy: Oncology · 2026 · Same journal
• CART-immune-related adverse events after BCMA CAR-T therapy · Molecular Therapy: Oncology · 2026 · Same journal
• Unmasking Wnt-driven HCC: Inhibiting SMYD2 to overcome immune resistance · Molecular Therapy: Oncology · 2026 · Same journal
• Intraperitoneal delivery of the oncolytic virus CF17 improves tumor immunogenicity and survival in gastric cancer peritoneal metastasis · Molecular Therapy: Oncology · 2026 · Same journal
• Synergistic Cell-Cycle Repression by HDAC/EZH2 Co-Targeting in H3K27-Altered Diffuse Midline Glioma · Molecular Therapy: Oncology · 2026 · Same journal
• Natural killer cell-derived extracellular vesicles reprogram cellular human immunity to enhance tumor cytotoxicity · Molecular Therapy: Oncology · 2026 · Same journal
• CAR design equips diverse immune cells with unique antigen-specific activation identities · Molecular Therapy: Oncology · 2026 · Same journal
• Optimizing CAR T cell therapy in pancreatic cancer through clinically actionable combinations · Molecular Therapy: Oncology · 2026 · Same journal